Bravecto

RSS

fluralaner

Authorised
This medicine is authorised for use in the European Union.

Overview

Bravecto is a veterinary medicine used to treat parasitic infestations in dogs and cats. It may be used:

• to treat flea and tick infestations in dogs and cats;

• as part of the management of flea allergy dermatitis (an allergic reaction to flea bites) in dogs and cats;

• to treat demodectic and sarcoptic mange (skin infestation caused by two different mites) in dogs;

• to reduce the risk of infection with the parasite Babesia canis canis transmitted by Dermacentor reticulatus ticks in dogs;

• to treat ear mite infestations in cats.

Bravecto contains the active substance fluralaner.

This EPAR was last updated on 21/03/2022

Authorisation details

Product details
Name
Bravecto
Agency product number
EMEA/V/C/002526
Active substance
fluralaner
International non-proprietary name (INN) or common name
fluralaner
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BE02
Publication details
Marketing-authorisation holder
Intervet International B.V
Revision
17
Date of issue of marketing authorisation valid throughout the European Union
11/02/2014
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

01/02/2022 Bravecto - EMEA/V/C/002526 - II/0051

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Ectoparasiticides for systemic use

  • Isoxazolines

Therapeutic indication

Dogs:

- For the treatment of tick and flea infestations;

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

- For the treatment of demodicosis caused by Demodex canis;

- For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.

- For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus. [chewable tablets only]

Cats:

- For the treatment of tick and flea infestations;

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

- For the treatment of infestations with ear mites (Otodectes cynotis).

Assessment history

Changes since initial authorisation of medicine

News

Related content

How useful was this page?

Add your rating
Average
4 ratings
1 rating
1 rating
1 rating
1 rating